Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -113.05% is 83% below its 5-year average of -61.88%, near the low end of its 5-year range (-113.41%–-17.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.45% below its 12-month average of -105.21%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -113.05%.
RETURN ON EQUITY (ROE)
-113.05%
RETURN ON EQUITY (ROE) AVG TTM
-105.21%
RETURN ON EQUITY (ROE) AVG 3Y
-79.72%
RETURN ON EQUITY (ROE) AVG 5Y
-61.88%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.45%
CURRENT VS 3Y AVG
-41.81%
CURRENT VS 5Y AVG
-82.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-169.10%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$693.19M
Return on Equity (ROE)
-113.05%
TTM Avg
-105.21%
3Y Avg
-79.72%
5Y Avg
-61.88%
Market Cap
$693.61M
Return on Equity (ROE)
-44.64%
TTM Avg
-42.57%
3Y Avg
32.15%
5Y Avg
-68.82%
Market Cap
$691.79M
Return on Equity (ROE)
-47.51%
TTM Avg
-32.80%
3Y Avg
-39.18%
5Y Avg
-31.37%
Market Cap
$694.79M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$685.49M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
Market Cap
$702.82M
Return on Equity (ROE)
-44.63%
TTM Avg
-42.69%
3Y Avg
-38.09%
5Y Avg
-55.51%
Market Cap
$681.27M
Return on Equity (ROE)
-55.36%
TTM Avg
-93.85%
3Y Avg
-76.06%
5Y Avg
-67.62%
Market Cap
$681.02M
Return on Equity (ROE)
-405.51%
TTM Avg
42.95%
3Y Avg
-55.53%
5Y Avg
-60.37%
Market Cap
$709.65M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $693.19M | -113.05% | -105.21% | -79.72% | -61.88% |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | -44.64% | -42.57% | 32.15% | -68.82% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | -47.51% | -32.80% | -39.18% | -31.37% |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | -25.03% | -10.49% | -5.87% | -23.97% |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | -44.63% | -42.69% | -38.09% | -55.51% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -55.36% | -93.85% | -76.06% | -67.62% |
| Verastem, Inc. (VSTM)vs › | $681.02M | -405.51% | 42.95% | -55.53% | -60.37% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 15.36% | 25.54% | 15.72% | 18.75% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 2.89% | 20.45% | 11.91% | -3.26% |
ROE
-113.0%
ROA
-103.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -113.05% |
| 2026-03-31 | -96.48% |
| 2025-12-31 | -113.41% |
| 2025-09-30 | -104.92% |
| 2025-06-30 | -98.20% |
| 2025-03-31 | -90.75% |
| 2024-12-31 | -78.56% |
| 2024-09-30 | -65.10% |
| 2024-06-30 | -56.85% |
| 2024-03-31 | -54.58% |
| 2023-12-31 | -52.55% |
| 2023-09-30 | -54.82% |
| 2023-06-30 | -57.08% |
| 2023-03-31 | -48.88% |
| 2022-12-31 | -46.99% |
| 2022-09-30 | -40.11% |
| 2022-06-30 | -33.35% |
| 2022-03-31 | -30.47% |
| 2021-12-31 | -25.11% |
| 2021-09-30 | -20.98% |
| 2021-06-30 | -17.31% |
| 2021-03-31 | -13.65% |
| 2020-12-31 | -126.47% |
